Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 867

Results For "C"

9533 News Found

Abbott receives FDA clearance for its imaging tech using AI
Digitisation | August 04, 2021

Abbott receives FDA clearance for its imaging tech using AI

Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -


Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22
News | August 04, 2021

Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22

Aditya Puri former MD of HDFC bank joins Solara board as chairman


Mindpeers launches on-demand behavioural healthcare platform
Healthcare | August 04, 2021

Mindpeers launches on-demand behavioural healthcare platform

It is designed to tackle mental health issues


Alkem launch two drugs in US
News | August 04, 2021

Alkem launch two drugs in US

Ibuprofen and Famotidine tablets approved by FDA


NATCO Pharma transfers Lenalidomide ANDA to Arrow
News | August 04, 2021

NATCO Pharma transfers Lenalidomide ANDA to Arrow

Arrow is the marketing partner in US


Wipro GE Healthcare introduces remote monitoring solution for COVID 19
Healthcare | August 04, 2021

Wipro GE Healthcare introduces remote monitoring solution for COVID 19

Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution


Evexia Lifecare to manufacture API of Isometa
News | August 03, 2021

Evexia Lifecare to manufacture API of Isometa

Robust demand for the product across the Middle East, Africa and Latin America


Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
Healthcare | August 03, 2021

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22

Nureca Ltd has reported financial results for the period ended June 30, 2021.


PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya
Policy | August 03, 2021

PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya

The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | August 03, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.